Implications of the reduction in prostate cancer screening using prostate-specific antigen

Alexandros A. Tzovarasa First Medical Oncology Clinic, Saint-Savvas Cancer Hospital L. Alexandras 171, Athens11522, GreeceCorrespondence[email protected]

Eleni Karatrasogloub First Medical Oncology Clinic, Saint-Savvas Cancer Hospital, Athens, Greece

Sofia Talaganib First Medical Oncology Clinic, Saint-Savvas Cancer Hospital, Athens, Greece

Konstantina Perdikarib First Medical Oncology Clinic, Saint-Savvas Cancer Hospital, Athens, Greece

Christos Verosb First Medical Oncology Clinic, Saint-Savvas Cancer Hospital, Athens, Greece

Michail Nikolaoub First Medical Oncology Clinic, Saint-Savvas Cancer Hospital, Athens, Greece

References

Scailteux LM, Capelle V, Balusson F, et al. Changes in prostate cancer screening practice by blood PSA testing between 2011 and 2017, a French population-based study. Curr Med Res Opin. 2021;37(8):1435–1441.
PubMed Web of Science ®Google Scholar
Welch HG, Albertsen PC. Reconsidering prostate cancer mortality – the Future of PSA Screening. N Engl J Med. 2020;382(16):1557–1563.
PubMed Web of Science ®Google Scholar
Xu B, Li G, Kong C, et al. A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting. Curr Med Res Opin. 2021;37(9):1617–1625.
PubMedGoogle Scholar
Limburg PJ, Finney Rutten LJ, Ozbay AB, et al. Recent trends in colorectal cancer screening methods based on Medicare claims data. Curr Med Res Opin. 2021;37(4):605–607.
PubMedGoogle Scholar
Fisher DA, Saoud L, Finney Rutten LJ, et al. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model. Curr Med Res Opin. 2021;37(6):1005–1010.
PubMedGoogle Scholar
Freedland SJ, Li S, Pilon D, et al. Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. Curr Med Res Opin. 2021;37(4):635–642.
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Implications of the reduction in prostate cancer screening using prostate-specific antigen

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Implications of the reduction in prostate cancer screening using prostate-specific antigen

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date